Home Situations SMMT — Profile and price weak
Situation · 2026-06-12

SMMT — Profile and price weak

Discounted for a Reason: No Quality, No Stability

Updated 2026-06-08 · Ref: Biotechnology
Key metrics — 2026-06-08
Peer score
34
Quality pct
38
Valuation pct
30
52w drawdown
-51.9%
21d vs sector
-15.4%
Peer group
Biotechnology
Situation summary

Summit is cheap because the business model delivers neither quality nor stability. ROE at -270.95% and 82.7% volatility put the stock at the far end of risk. This is a pre-commercial biotech betting everything on one oncology asset. Cheap is not the same as undervalued.

Published by AssetNext · 2026-05-24

All companies with this signal today

View full list: Profile and price weak →

Related pages for SMMT
Full peer analysis for Summit Therapeutics Inc. →Similar companies to SMMTSMMT peersAll SMMT comparisonsRussell 1000 context
Signal history — last 30 days
Date Signal Peer score Drawdown 21d vs sector
2026-06-08 Profile and price weak 34 -51.9% -15.4%
2026-06-01 Profile and price weak 34 -46.4% -32.2%
2026-05-26 Profile and price weak 34 -42.0% -22.7%
2026-05-20 Profile and price weak 34 -39.0% -35.9%

See SMMT's full peer analysis

Break down SMMT's structural position across all peer dimensions with the interactive app.

Open SMMT in AssetNext →